Skip to main content

Consolidation History in the Bioinformatics Sector, as Tracked by BioInform, 2000-2003

Premium

2000
March: Paracel acquired by Celera Genomics (deal worth $283M)

August: Oxford Molecular acquired by Pharmacopeia (deal worth $27M)

September: Neomorphic acquired by Affymetrix (deal worth $70M)

October: Empaheon acquired by eBioinformatics (deal worth $11M)

December: Proteome acquired by Incyte (deal worth $77M)

 

2001
May:
Rosetta Inpharmatics acquired by Merck (deal worth $620M)

July: Synomics acquired by Accelrys (deal worth $4M)

July: Momentum acquired by Cellomics

November: Genomica acquired by Exelixis (deal worth $110M)

 

2002
January:
NetGenics acquired by Lion Bioscience (deal worth $17M)

February: ProteoMetrics closes, software acquired by Genomic Solutions (value not disclosed)

March: Entigen ceases operations

March: DoubleTwist closes

December: InforMax acquired by Invitrogen (deal worth $42M)

 

2003
January:
Structural Genomics, GeneFormatics plan merger

February: Viaken Systems closes

February: Phase-it acquired by Europroteome (value not disclosed)

March: Molecular Mining closes

April: Argentys (formerly Blackstone) acquired by TurboWorx (value not disclosed)

April: LabBook discontinues retail operations; Rescentris licenses technology

 

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.